关注黄病毒：当前和未来的药物靶点。
Focus on flaviviruses: current and future drug targets.
机构信息
Department of Biochemistry & Molecular Biology, Colorado State University, Fort Collins, CO 80523, USA.
出版信息
Future Med Chem. 2009 May;1(2):327-44. doi: 10.4155/fmc.09.27.
BACKGROUND
Infection by mosquito-borne flaviviruses (family Flaviviridae) is increasing in prevalence worldwide. The vast global, social and economic impact due to the morbidity and mortality associated with the diseases caused by these viruses necessitates therapeutic intervention. There is currently no effective clinical treatment for any flaviviral infection. Therefore, there is a great need for the identification of novel inhibitors to target the virus life cycle.
DISCUSSION
In this article, we discuss structural and nonstructural viral proteins that are the focus of current target validation and drug discovery efforts. Both inhibition of essential enzymatic activities and disruption of necessary protein–protein interactions are considered. In addition, we address promising new targets for future research.
CONCLUSION
As our molecular and biochemical understanding of the flavivirus life cycle increases, the number of targets for antiviral therapeutic discovery grows and the possibility for novel drug discovery continues to strengthen.
背景
在世界范围内，由蚊媒黄病毒（黄病毒科）引起的感染越来越普遍。这些病毒引起的疾病的发病率和死亡率给全球带来了巨大的社会和经济影响，因此需要进行治疗干预。目前，还没有针对任何黄病毒感染的有效临床治疗方法。因此，迫切需要鉴定针对病毒生命周期的新型抑制剂。
讨论
本文讨论了目前作为目标验证和药物发现工作重点的结构和非结构病毒蛋白。既考虑了对必要酶活性的抑制，也考虑了对必需蛋白-蛋白相互作用的破坏。此外，我们还讨论了未来研究有前途的新靶点。
结论
随着我们对黄病毒生命周期的分子和生化理解的增加，抗病毒治疗发现的靶标数量不断增加，新型药物发现的可能性也不断增强。
Zotero 插件